跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2011/11/002147
CTRI/2011/11/002147已完成2 期

A multicentric prospective randomized double blind parallel group active controlled study to evaluate the safety and efficacy of ZYH7 compared to Fenofibrate in patients with dyslipidemia

Cadila Health care Ltd0 个研究点目标入组 100 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
100
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •Inclusion criteria :
  • •1.Age 18-65 years
  • •2.Subjects of either gender, males or females
  • •3.Triglycerides more than or equal to 200 to 500 mg/dl on screening visit.
  • •4.Body mass index (BMI) more than 23 kg/m2
  • •5.If subject is diabetic, he should be controlled on a maximum of two oral anti diabetic agents except Thiazolidinedione.
  • •6.Subject has given informed consent for participation in this trial.

排除标准

  • •Exclusion criteria :
  • •1.Pregnancy and lactation.
  • •2.History of more than 5% weight loss in past 6 months.
  • •3.Subjects on treatment with insulin and PPAR alpha or gamma agonist in the past 3 month.
  • •4.Subjects having unstable angina, acute myocardial infarction in past 3 months or heart failure of NYHA class (III-IV).
  • •5.Uncontrolled hypertension ( more than 150/100 mm of Hg).( If Subject using Thiazides, ACE inhibitors, beta blockers they should be on minimum 3 month stable therapy and treatment not expected to change during trial participation)
  • •6.History of clinically significant edema.
  • •7.History of pancreatitis or gall stone diseases.
  • •8.Subject having thyroid-stimulating hormone (TSH) levels outside normal reference range, Subjects who are clinically euthyroid and on stable thyroid replacement therapy for 2 months prior to screening and who are anticipated to remain on this dose throughout the trial period will be allowed.
  • •9.Uncontrolled diabetes (HbA1c more than or equal to 9 gm %).
  • •10.History of active liver disease or hepatic dysfunction demonstrated by AST and ALT more than or equal to 2.5 times of upper normal limit (UNL) or bilirubin more than or equal to 2 times UNL in the past 3 months.
  • •11.Renal dysfunction demonstrated by abnormal GFR (more than 60 ml per min) or presence of ketonuria.
  • •12.History of myopathies or evidence of active muscle diseases demonstrated by CPK more than or equal to 10 times UNL.
  • •13.History of any other concurrent serious illness (e.g. tuberculosis, HIV, malignancy, etc).
  • •14.History of alcohol and/or drug abuse.
  • •15.History of known allergy, sensitivity or intolerance to the study drugs and their formulation ingredients.
  • •16.Subjects on any other lipid lowering medications.
  • •17.If on contraceptive or hormone replacement therapy (HRT), therapy started or changed in last 3 months.
  • •18.Prolonged use of steroids (more than 15 days) in last 3 months (topical preparations, nasal and intra-articular administration are permitted).
  • •19.History of long term use of non-steroidal anti-inflammatory drugs. (more than 1month)
  • •20.Participation in any other clinical trial in the past 3 months
  • •21.Unable to give informed consent and follow protocol requirements.

研究者

发起方
Cadila Health care Ltd

相似试验

已完成
4 期
A clinical trial to study the effect of, Fluticasone Nasal Spray BP (Mfd. By Biodeal Laboratories Pvt. Ltd.) Vs Fluticasone Nasal Spray BP (Mfd. By Glaxosmithkline Pharmaceuticals Ltd) in patients with Allergic Rhinitis
CTRI/2010/091/000135Biodeal Laboratories Pvt. Ltd508, G.I.D.C Estate, Wadhwan City, Dist Surendranagar,Gujarat - 363035125
已完成
不适用
The influence of two policies of closure of the laparotomy wound in the rate of surgical site infection in colorectal cancer surgery: the New Operation trialColorectal cancerMalignant neoplasm of rectosigmoid junctionCancer
ISRCTN19463413Carlos III Institute of Health (Instituto de Salud Carlos III) (Spain)738
已完成
3 期
Ketorolac 30 mg Sublingual tablet in the Acute treatment of Migraine headache.
CTRI/2021/04/032664Troikaa Pharmaceuticals Ltd
进行中（未招募）
1 期
A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N versus CustodiolPatients with aortic valve disease and has to undergo aortic valve surgery +/- bypass surgery.
EUCTR2012-003776-40-DEDr. Franz Köhler Chemie GmbH530
进行中（未招募）
不适用
A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N versus Custodiol
EUCTR2008-005992-81-DEDr. F. Köhler Chemie GmbH